Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

Within the past years there have been substantial changes to our understanding of haematopoiesis and cells that initiate and sustain leukemia. Recent studies have revealed that developing haematopoietic stem and progenitor cells are much more heterogeneous and versatile than has been previously thought. This versatility includes cells using more than one route to a fate and cells having progressed some way towards a cell type retaining other lineage options as clandestine. These notions impact substantially on our understanding of the origin and nature of leukemia. An important question is whether leukemia stem cells are as versatile as their cell of origin as an abundance of cells belonging to a lineage is often a feature of overt leukemia. In this regard, we examine the coming of age of the “leukemia stem cell” theory and the notion that leukemia, like normal haematopoiesis, is a hierarchically organized tissue. We examine evidence to support the notion that whilst cells that initiate leukemia have multi-lineage potential, leukemia stem cells are reprogrammed by further oncogenic insults to restrict their lineage decision-making. Accordingly, evolution of a sub-clone of lineage-restricted malignant cells is a key feature of overt leukemia.

[1]  K. Toellner,et al.  Versatility of stem and progenitor cells and the instructive actions of cytokines on hematopoiesis , 2015, Critical reviews in clinical laboratory sciences.

[2]  Alba Rodriguez-Meira,et al.  Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. , 2015, Seminars in cancer biology.

[3]  I. Sánchez-García How tumour cell identity is established? , 2015, Seminars in cancer biology.

[4]  A. Gentles,et al.  Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages , 2015, Proceedings of the National Academy of Sciences.

[5]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[6]  D. Sahoo,et al.  Identification and Specification of the Mouse Skeletal Stem Cell , 2015, Cell.

[7]  K. Akashi,et al.  The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. , 2014, Experimental hematology.

[8]  T. Miyamoto,et al.  Hematopoietic stem cell aging and chronic lymphocytic leukemia pathogenesis , 2014, International Journal of Hematology.

[9]  W. C. Chan,et al.  Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma , 2014, Nature Communications.

[10]  M. Berger,et al.  Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia , 2014, Science Translational Medicine.

[11]  O. Griffith,et al.  Mitelman Database (Chromosome Aberrations and Gene Fusions in Cancer) , 2014 .

[12]  Thomas J. Hudson,et al.  Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.

[13]  A. Mead,et al.  Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate , 2014, The Journal of experimental medicine.

[14]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[15]  O. Nureki,et al.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[16]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[17]  I. Macaulay,et al.  Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy , 2013, Nature.

[18]  T. Graf,et al.  CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. , 2013, Blood.

[19]  I. Sánchez-García,et al.  Function of oncogenes in cancer development: a changing paradigm , 2013, The EMBO journal.

[20]  S. Nutt,et al.  M-CSF instructs myeloid lineage fate in single haematopoietic stem cells , 2013, Nature.

[21]  Paul Bertone,et al.  Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. , 2013, Genes & development.

[22]  I. Sánchez-García,et al.  p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice , 2013, Cell cycle.

[23]  Ash A. Alizadeh,et al.  Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation , 2012, Nature Communications.

[24]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[25]  I. González-Herrero,et al.  Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB , 2012, Cell Cycle.

[26]  D. Weinstock,et al.  The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. , 2012, Blood.

[27]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[28]  Diego Alonso-López,et al.  A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors , 2012, The EMBO journal.

[29]  P. Gaulard,et al.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. , 2012, Blood.

[30]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[31]  I. Lossos,et al.  Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice , 2012, Proceedings of the National Academy of Sciences.

[32]  W. Carroll,et al.  Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. , 2012, Blood.

[33]  José Alberola-lla,et al.  CD86 is expressed on murine hematopoietic stem cells and denotes lymphopoietic potential. , 2012, Blood.

[34]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[35]  W. Chan,et al.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[36]  Christian Bastard,et al.  TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.

[37]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[38]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[39]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[40]  Konstantinos J. Mavrakis,et al.  The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma , 2011, Cell.

[41]  Lia S. Campos,et al.  Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1 , 2011, Proceedings of the National Academy of Sciences.

[42]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[43]  K. Akashi,et al.  Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. , 2011, Cancer cell.

[44]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[45]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[46]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[47]  Li Ding,et al.  Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.

[48]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[49]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[50]  Joelle M. Kalicki-Veizer,et al.  Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome , 2010 .

[51]  P. Hughes,et al.  The versatility of haematopoietic stem cells: implications for leukaemia , 2010, Critical reviews in clinical laboratory sciences.

[52]  P. Ye,et al.  Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. , 2010, Cancer research.

[53]  Nathan C Boles,et al.  Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. , 2010, Cell stem cell.

[54]  Scott W. Lowe,et al.  Stem cells: The promises and perils of p53 , 2009, Nature.

[55]  S. Ogawa,et al.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.

[56]  Philipp S. Hoppe,et al.  Hematopoietic Cytokines Can Instruct Lineage Choice , 2009, Science.

[57]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[58]  I. Sánchez-García,et al.  B‐cell acute lymphoblastic leukaemia: towards understanding its cellular origin , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[59]  H. Kawamoto,et al.  A new paradigm for hematopoietic cell lineages: revision of the classical concept of the myeloid-lymphoid dichotomy. , 2009, Trends in immunology.

[60]  M. Pérez-Caro,et al.  Stem-cell driven cancer: "Hands-off" regulation of cancer development , 2009, Cell cycle.

[61]  Rhodri Ceredig,et al.  Models of haematopoiesis: seeing the wood for the trees , 2009, Nature Reviews Immunology.

[62]  M. Piris,et al.  Cancer induction by restriction of oncogene expression to the stem cell compartment , 2008, The EMBO journal.

[63]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[64]  K. Akashi,et al.  The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. , 2007, Blood.

[65]  M. Blagosklonny Cancer stem cell and cancer stemloids: From biology to therapy , 2007, Cancer biology & therapy.

[66]  Junia V. Melo,et al.  Chronic myeloid leukaemia as a model of disease evolution in human cancer , 2007, Nature Reviews Cancer.

[67]  T. Graf,et al.  Early decisions in lymphoid development. , 2007, Current opinion in immunology.

[68]  M. Blagosklonny Target for cancer therapy: proliferating cells or stem cells , 2006, Leukemia.

[69]  A. Rolink,et al.  A B220+ CD117+ CD19± hematopoietic progenitor with potent lymphoid and myeloid developmental potential , 2005, European journal of immunology.

[70]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[71]  A. Rolink,et al.  The earliest subpopulation of mouse thymocytes contains potent T, significant macrophage, and natural killer cell but no B-lymphocyte potential. , 2005, Blood.

[72]  M. Bevan,et al.  Notch ligands Delta 1 and Jagged1 transmit distinct signals to T-cell precursors. , 2005, Blood.

[73]  L. Chin,et al.  Nuclear cloning of embryonal carcinoma cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Rudolf Jaenisch,et al.  Reprogramming of a melanoma genome by nuclear transplantation. , 2004, Genes & development.

[75]  Thomas M. Schmitt,et al.  Heterogeneity among DN1 prothymocytes reveals multiple progenitors with different capacities to generate T cell and non-T cell lineages. , 2004, Immunity.

[76]  T. Curran,et al.  Mouse embryos cloned from brain tumors. , 2003, Cancer research.

[77]  Y. Katsura Redefinition of lymphoid progenitors , 2002, Nature Reviews Immunology.

[78]  I. Weissman,et al.  AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[79]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[80]  H. Macdonald,et al.  Deficient T cell fate specification in mice with an induced inactivation of Notch1. , 1999, Immunity.

[81]  I. Weissman,et al.  Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow , 1997, Cell.

[82]  K. Akashi,et al.  Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.

[83]  D. Metcalf Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Shankland Differentiation of the O and P cell lines in the embryo of the leech. II. Genealogical relationship of descendant pattern elements in alternative developmental pathways. , 1987, Developmental biology.

[85]  D. Metcalf,et al.  Clonal analysis of progenitor cell commitment to granulocyte or macrophage production , 1982, Journal of cellular physiology.

[86]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[87]  F. Mitelman,et al.  Mitelman database of chromosome aberrations and gene fusions in cancer , 2014 .

[88]  J. Salk Clonal evolution in cancer , 2010 .

[89]  I. Weissman,et al.  Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. , 2001, Annual review of cell and developmental biology.